112 results on '"Robertsen, Ida"'
Search Results
2. Intraindividual Variability in Absolute Bioavailability and Clearance of Midazolam in Healthy Individuals
3. Neither Gastric Bypass Surgery Nor Diet-Induced Weight-Loss Affect OATP1B1 Activity as Measured by Rosuvastatin Oral Clearance
4. Correlations between 4β-hydroxycholesterol and hepatic and intestinal CYP3A4: protein expression, microsomal ex vivo activity, and in vivo activity in patients with a wide body weight range
5. Oral Drug Dosing After Gastric Bypass and Diet‐Induced Weight Loss: Simpler Than We Think? Lessons Learned From the COCKTAIL Study.
6. Impact of Fasting Status and Circadian Variation on the Pharmacokinetics of Mycophenolate Mofetil and the Glucuronide Metabolite in Renal Transplant Recipients
7. Response to: “Utility of endogenous 4β-hydroxycholesterol as a biomarker to assess cytochrome P 450 3A (CYP3A) activity: not quite ready for prime time”
8. Correlation of Body Weight and Composition With Hepatic Activities of Cytochrome P450 Enzymes
9. A Limited Sampling Strategy to Estimate Exposure of Everolimus in Whole Blood and Peripheral Blood Mononuclear Cells in Renal Transplant Recipients Using Population Pharmacokinetic Modeling and Bayesian Estimators
10. Severe Mycophenolate Intoxication in a Solid Organ Transplant Recipient—No Intervention Actually Needed
11. Measuring Intracellular Concentrations of Calcineurin Inhibitors: Expert Consensus from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology Expert Panel
12. Tacrolimus Area Under the Concentration Versus Time Curve Monitoring, Using Home-Based Volumetric Absorptive Capillary Microsampling
13. Determination of Tacrolimus Concentration and Protein Expression of P-glycoprotein in Single Human Renal Core Biopsies
14. High-Dose Fish Oil Supplementation Increase Tacrolimus Exposure in Stable Renal Transplant Recipients
15. High Tacrolimus Clearance – A Risk Factor for Development of Interstitial Fibrosis and Tubular Atrophy in the Transplanted Kidney
16. A Limited Sampling Strategy to Estimate Whole Blood and Intra-lymphocyte Exposure of Everolimus in Renal Transplant Recipients using Population Pharmacokinetic Modeling and Bayesian Estimators
17. The Authors’ Reply
18. How to Report and Interpret Bioequivalence Data in Solid Organ Transplant Recipients
19. A Method for Evaluating Robustness of Limited Sampling Strategies—Exemplified by Serum Iohexol Clearance for Determination of Measured Glomerular Filtration Rate.
20. Impact of type 2 diabetes on in vivo activities and protein expressions of cytochrome P450 in patients with obesity.
21. Short‐ and long‐term effects of body weight, calorie restriction and gastric bypass on CYP1A2, CYP2C19 and CYP2C9 activity.
22. Drug Disposition Protein Quantification in Matched Human Jejunum and Liver From Donors With Obesity.
23. Short‐ and long‐term effects of body weight loss following calorie restriction and gastric bypass on CYP3A‐activity – a non‐randomized three‐armed controlled trial.
24. Poster Board #-Session: P41-I Rimonabant Affects Cyclosporine A, but Not Tacrolimus Pharmacokinetics in Renal Transplant Recipients.: Abstract# 698
25. Proteomics‐Informed Prediction of Rosuvastatin Plasma Profiles in Patients With a Wide Range of Body Weight.
26. Fasting Status and Circadian Variation Must be Considered When Performing AUC‐based Therapeutic Drug Monitoring of Tacrolimus in Renal Transplant Recipients.
27. Chronic Inhibition of CYP3A is Temporarily Reduced by Each Hemodialysis Session in Patients With End‐Stage Renal Disease.
28. Increased systemic exposure of once‐daily tacrolimus in renal transplant recipients on marine omega‐3 fatty acid supplementation.
29. A287 Effect of Gastric Bypass and Very-Low Energy Diet on cardiometabolic risk factors
30. The influence of bariatric surgery on oral drug bioavailability in patients with obesity: A systematic review.
31. Efficacy and Safety of Empagliflozin in Renal Transplant Recipients With Posttransplant Diabetes Mellitus.
32. High tacrolimus clearance – a risk factor for development of interstitial fibrosis and tubular atrophy in the transplanted kidney: a retrospective single‐center cohort study.
33. High Tacrolimus Clearance Is a Risk Factor for Acute Rejection in the Early Phase After Renal Transplantation.
34. Closer to the Site of Action: Everolimus Concentrations in Peripheral Blood Mononuclear Cells Correlate Well With Whole Blood Concentrations.
35. Use of Generic Tacrolimus in Elderly Renal Transplant Recipients.
36. More Potent Lipid-Lowering Effect by Rosuvastatin Compared With Fluvastatin in Everolimus-Treated Renal Transplant Recipients.
37. Rimonabant Affects Cyclosporine A, but Not Tacrolimus Pharmacokinetics in Renal Transplant Recipients.
38. Why dose adjust systemic exposure when looking for associations with adverse events in tacrolimus‐treated transplant recipients?
39. Reply to letter: "What about drug bioavailability in patients who had bariatric surgery and dependent on immunosuppressives?".
40. The Importance of Using Serially Measured Tacrolimus Clearance Values, Especially During the Early Posttransplantation Period.
41. Generiske legemidler - ikke så like som vi tror?
42. A5160 - The influence of bariatric surgery on the pharmacokinetics of drugs in patients with obesity - a systematic review of the literature.
43. Gastric Bypass vs Diet and Cardiovascular Risk Factors: A Nonrandomized Controlled Trial.
44. Impact of type 2 diabetes on in vivo activities and protein expressions of cytochrome P450 in patients with obesity.
45. Fasting Status and Circadian Variation Must be Considered When Performing AUC-based Therapeutic Drug Monitoring of Tacrolimus in Renal Transplant Recipients.
46. A Comparative Analysis of Cytochrome P450 Activities in Paired Liver and Small Intestinal Samples from Patients with Obesity.
47. Generic drugs – not as equivalent as we think?
48. Measured GFR by Utilizing Population Pharmacokinetic Methods to Determine Iohexol Clearance.
49. Efficacy and Safety of Empagliflozin in Renal Transplant Recipients With Posttransplant Diabetes Mellitus.
50. Impact of body weight, low energy diet and gastric bypass on drug bioavailability, cardiovascular risk factors and metabolic biomarkers: protocol for an open, non-randomised, three-armed single centre study (COCKTAIL).
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.